Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific agrees purchase deal for Atritech

Boston Scientific agrees purchase deal for Atritech

20th January 2011

Boston Scientific has signed a definitive merger agreement that will see it acquire fellow medical device manufacturer Atritech.

The deal is worth up to a potential $375 million (234.4 million pounds), including an upfront fee of $100 million and additional milestone-based payments, with the transaction expected to close during the first quarter of the year.

Atritech is the developer of Watchman, a novel device that closes the left atrial appendage as a means of treating atrial fibrillation patients at risk of ischemic stroke.

It has been CE Mark-accredited since 2009 and is the first medical device that is clinically proven to offer a viable alternative to anticoagulant drugs in treating the disease.

Ray Elliott, president and chief executive officer of Boston Scientific, said: "This is an important acquisition in the fast-growing areas of atrial fibrillation and structural heart therapy, both of which are among our priority growth initiatives."

This comes after the firm agreed a deal earlier this month to acquire Intelect Medical, which manufactures neuromodulation technologies with applications in deep brain stimulation treatments.ADNFCR-8000103-ID-800354593-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.